Expanding a Comprehensive Platform to Support the Future of Cell and Gene Therapies

WuXi Advanced Therapies (ATU) CEO David Y. H. Chang discusses the past, present, and future of cell and gene therapy and how WuXi ATU is building a platform to support forthcoming innovations.

    • Tags:

Nice Insight

Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.

Q: